ME Stock - 23andMe Holding Co.
Unlock GoAI Insights for ME
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $189.90M | $219.64M | $299.49M | $271.89M | $243.92M |
| Gross Profit | $100.00M | $99.38M | $134.50M | $132.94M | $117.01M |
| Gross Margin | 52.7% | 45.2% | 44.9% | 48.9% | 48.0% |
| Operating Income | $-240,640,000 | $-321,356,000 | $-324,011,000 | $-254,153,000 | $-185,196,000 |
| Net Income | $-280,885,000 | $-666,704,000 | $-311,656,000 | $-217,490,000 | $-183,364,000 |
| Net Margin | -147.9% | -303.5% | -104.1% | -80.0% | -75.2% |
| EPS | $-10.88 | $-27.59 | $-13.81 | $-9.96 | $-9.02 |
23andMe Holding Co. operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications based on genetic testing of a saliva sample through its spit kit. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to improve patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing of intellectual property associated with identified drug targets related to drug candidates under clinical development. It has a collaboration agreement with GlaxoSmithKline Intellectual Property (No.3) Limited to leverage genetic insights to validate, develop, and commercialize drugs. The company was founded in 2006 and is headquartered in South San Francisco, California.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 29th 2022 | Berenberg | Initiation | Buy | $7 |
| September 22nd 2022 | Cowen | Initiation | Outperform | $6 |
Earnings History & Surprises
MEEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2025 | Aug 4, 2025 | — | $-0.00 | — | — |
Q2 2025 | Jun 11, 2025 | — | $-3.85 | — | — |
Q1 2025 | Jan 28, 2025 | $-3.19 | $-1.02 | +68.0% | ✓ BEAT |
Q4 2024 | Nov 12, 2024 | $-3.15 | $-2.32 | +26.4% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $-0.22 | $-2.80 | -1172.7% | ✗ MISS |
Q2 2024 | May 23, 2024 | $-0.15 | $-2.40 | -1500.0% | ✗ MISS |
Q1 2024 | Feb 7, 2024 | $-0.14 | $-3.40 | -2328.6% | ✗ MISS |
Q4 2023 | Nov 8, 2023 | $-0.14 | $-3.20 | -2185.7% | ✗ MISS |
Q3 2023 | Aug 8, 2023 | $-0.15 | $-4.40 | -2833.3% | ✗ MISS |
Q2 2023 | May 25, 2023 | $-0.16 | $-2.80 | -1650.0% | ✗ MISS |
Q1 2023 | Feb 8, 2023 | $-0.19 | $-4.00 | -2005.3% | ✗ MISS |
Q4 2022 | Nov 7, 2022 | $-0.17 | $-3.00 | -1664.7% | ✗ MISS |
Q3 2022 | Aug 8, 2022 | $-0.16 | $-4.00 | -2400.0% | ✗ MISS |
Q2 2022 | May 26, 2022 | $-0.13 | $-2.60 | -1900.0% | ✗ MISS |
Q1 2022 | Feb 10, 2022 | $-0.16 | $-4.20 | -2525.0% | ✗ MISS |
Q4 2021 | Nov 10, 2021 | $-0.11 | $-0.80 | -627.3% | ✗ MISS |
Q3 2021 | Aug 13, 2021 | — | $-5.00 | — | — |
Q2 2021 | Jun 3, 2021 | — | $-3.30 | — | — |
Q1 2021 | Mar 24, 2021 | — | $-2.20 | — | — |
Q4 2020 | Nov 16, 2020 | — | $-1.78 | — | — |
Latest News
Frequently Asked Questions about ME
What is ME's current stock price?
What is the analyst price target for ME?
What sector is 23andMe Holding Co. in?
What is ME's market cap?
Does ME pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to ME for comparison